Ascendiant Capital Maintains Buy on Surgepays, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital's analyst Edward Woo maintains a Buy rating on Surgepays (NASDAQ:SURG) but lowers the price target from $9.5 to $9.
September 11, 2024 | 10:00 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ascendiant Capital's analyst Edward Woo maintains a Buy rating on Surgepays but lowers the price target from $9.5 to $9, indicating a slight decrease in expected valuation.
The maintained Buy rating suggests continued confidence in Surgepays' potential, but the lowered price target indicates a slight reduction in expected future performance. This could lead to neutral short-term price movement as the market digests the mixed signals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100